Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Myricx: ADCs with a lipidation inhibitor payload

U.K.-based Myricx is turning a small molecule for parasitic diseases into an ADC payload for cancers

December 13, 2023 1:37 AM UTC

Myricx is pioneering a post-translational modification inhibitor of myristoylation as the payload for antibody-drug conjugates.

Myristoylation is a lipid modification involving the addition of myristic acid, a 14-carbon fatty acid, to the N-terminus of proteins, catalyzed by the enzymes NMT1 and NMT2. The modification dictates signal transduction, protein stability and localization of proteins to membranes. About 150 human proteins are myristoylated...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article